

**MEETING REPORT ON
FRAMEWORK FOR METRICS TO SUPPORT
EFFECTIVE TREATMENT AS PREVENTION**

2–3 APRIL 2012 GENEVA, SWITZERLAND



**World Health
Organization**

MEETING REPORT ON
FRAMEWORK FOR METRICS TO SUPPORT
EFFECTIVE TREATMENT AS PREVENTION

2–3 APRIL 2012 GENEVA, SWITZERLAND

MEETING REPORT ON
FRAMEWORK FOR METRICS TO SUPPORT
EFFECTIVE TREATMENT AS PREVENTION

2–3 APRIL 2012 GENEVA, SWITZERLAND

WHO Library Cataloguing-in-Publication Data

Meeting report on framework for metrics to support effective treatment as prevention, 2-3 April 2012 Geneva, Switzerland.

1.HIV infections – drug therapy. 2.HIV infections – prevention and control. 3.HIV infections – transmission. 4.Anti-retroviral agents – therapeutic use. 4. I.World Health Organization.

ISBN 978 92 4 150433 1

(NLM classification: WC 503.2)

© **World Health Organization 2012**

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Layout by L'IV Com Sàrl, Villars-sous-Yens, Switzerland.

Printed by the WHO Document Production Services, Geneva, Switzerland..

CONTENTS

Acronyms and abbreviations	2
I. Background of Treatment as Prevention (TasP) and the development of relevant metrics	3
A. What is TasP?	3
B. Implementing TasP for HIV infections at scale	4
C. A need for guidance in implementation and monitoring and evaluation (M&E)	5
D. Development of a TasP metrics framework	5
II. Programmatic context and implications for the development and application of TasP metrics	7
III. A monitoring and evaluation framework for TasP	11
A. Logical framework for TasP	11
B. Summary status of the feasibility of measuring logical framework indicators	12
C. General design considerations for impact evaluation of ART programmes	13
IV. Monitoring adverse events and unintended consequences to guide programmatic action	15
A. HIV drug resistance	15
B. Pharmacovigilance for adverse drug reactions to ART	17
C. Risk behaviour compensation	18
D. Monitoring the allocation of ART resources against national programme priorities	18
E. Ethical concerns	19
V. Use of clinical/community trials and mathematical models for measuring the impact of TasP	20
A. Current status of clinical and community trials on TasP	20
B. Types of mathematical models for TasP	21
C. Current status of mathematical modelling for TasP	21
D. Essential partnership between modelling/clinical trials, epidemiological and programmatic expertise	22
E. Moving toward more routine use of modelling for crude estimates of TasP impact	22
VI. Assessing country readiness for adopting essential TasP metrics	24
A. Checklist to estimate the readiness for measuring the effectiveness of TasP	24
B. Investing in stronger M&E systems for TasP	25
Annexes	26
Annex A. List of participants	26
Annex B. Indicator options for the TasP logical framework	28
Annex C. Checklist of routine monitoring indicators for ART cascade of services	30
References	32

ACRONYMS AND ABBREVIATIONS

ARI	annual risk of infection
ART	antiretroviral therapy
ARV	antiretroviral
EWI	early warning indicator
FSW	female sex worker
GARP	Global AIDS Response and Progress
HIV-DR	HIV drug resistance
HPTN	HIV Prevention Trials Network
HTC	HIV testing and counseling
LQAS	lot–quality assurance sampling
M&E	monitoring and evaluation
MMC	medical male circumcision
MSM	men who have sex with men
PEP	postexposure prophylaxis
PITC	provider-initiated testing and counselling
PLHIV	people living with HIV
PMTCT	prevention of mother-to-child transmission
PrEP	pre-exposure prophylaxis
PWID	people who inject drugs
STI	sexually transmitted infection
TasP	treatment as prevention
TB	tuberculosis
UTT	universal testing and treating
WHO	World Health Organization

I. BACKGROUND OF TREATMENT AS PREVENTION (TasP) AND THE DEVELOPMENT OF RELEVANT METRICS

A. WHAT IS TasP?

In this document, the term TasP refers to the use of antiretrovirals (ARVs) for treating people living with HIV (PLHIV). When ARVs are effective in reducing viral load, they also reduce a person's likelihood of transmitting HIV to others, independent of CD4 cell count.¹ TasP should not be perceived as being separate from the use of antiretroviral therapy (ART) for therapeutic benefits. It includes the use of ARVs for the prevention of HIV and tuberculosis (TB) (1) regardless of CD4 count but it does not include the use of ARVs for postexposure prophylaxis (PEP), pre-exposure prophylaxis (PrEP) and the use of ARV-based microbicides.

The factors that are critical for ART to reduce AIDS-related morbidity and mortality are consistent with those necessary for effective TasP, i.e. high coverage and quality across the cascade of services – from testing, linkage to care, initiation on ART, adherence to the regimen, monitoring viral suppression and early detection of drug resistance.

Assuming constant levels of risk behaviour and cofactors, such as the prevalence of sexually transmitted infections (STIs) and coverage of male circumcision, the potential number of HIV infections averted through the use of ARVs by PLHIV depends upon the number of individuals and unprotected contacts a person on ARVs is likely to have over a period of time, and the duration of time the infected person maintains viral suppression while on ARVs. Similarly, for vertical transmission, the number of infections averted among HIV-exposed infants is related to the proportion of infected pregnant women using ARVs during pregnancy and the period of breastfeeding. Optimizing the use of TasP at a programmatic level requires evidence-based decisions about which groups of PLHIV are prioritized for receiving ART, how early ART is initiated among PLHIV, and service delivery models to achieve and maintain viral load suppression through good adherence and clinical/laboratory monitoring of different types of patients on ART.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_28585

